IL-34: a novel differentiation therapy for AML?
- PMID: 37383007
- DOI: 10.1182/blood.2023020525
IL-34: a novel differentiation therapy for AML?
Comment on
-
TREM2 acts as a receptor for IL-34 to suppress acute myeloid leukemia in mice.Blood. 2023 Jun 29;141(26):3184-3198. doi: 10.1182/blood.2022018619. Blood. 2023. PMID: 37001042 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical